Anixa Biosciences
ANIX
13 hedge funds and large institutions have $673K invested in Anixa Biosciences in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
41% more capital invested
Capital invested by funds: $477K → $673K (+$196K)
1.43% more ownership
Funds ownership: 0% → 1.43% (+1.4%)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$70.4K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$750 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$19K |
| 2 |
First Manhattan
New York
|
-$13.3K |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
-$8.88K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.13K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
1
Bard Associates
Chicago,
Illinois
| $276K | -$8.88K | -1,600 | -3% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $185K | – | – | – |
|
|
DIA
3
Denver Investment Advisors
Denver,
Colorado
| $100K | – | – | – |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $68K | +$70.4K | +12,681 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $22K | -$6.13K | -1,103 | -21% |
|
|
BFA
6
BlackRock Fund Advisors
San Francisco,
California
| $12K | +$3K | +540 | +32% |
|
7
Wells Fargo
San Francisco,
California
| $4K | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $2K | -$761 | -137 | -25% |
|
|
EWM
9
Evercore Wealth Management
New York
| $2K | – | – | – |
|
|
10
First Manhattan
New York
| $1K | -$13.3K | -2,400 | -92% |
|
11
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
|
12
Morgan Stanley
New York
| – | -$19K | -5,000 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$3K | -800 | Closed |
|
|
14
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$750 | +135 | New |
|
ANIX Hedge Fund Activity: Q4 2016 in Review
13 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2016, worth a combined $673K — up 41% from $477K a quarter earlier.
Fund positioning in ANIX was balanced in Q4 2016: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $70.4K. The largest seller was Morgan Stanley, exiting entirely with an estimated $19K sold.
- 13 institutional investors held Anixa Biosciences (ANIX) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $673K of Anixa Biosciences stock for Q4 2016, up 41% quarter-over-quarter.
- 2 funds opened new Anixa Biosciences positions in Q4 2016 and 2 closed out, a net change of 0 holders.
- The largest Anixa Biosciences buyer in Q4 2016 was Vanguard Group, an estimated $70.4K added.
- The largest Anixa Biosciences seller in Q4 2016 was Morgan Stanley, an estimated $19K sold.
Based on aggregated 13F filings for Q4 2016.